Comparison of Biological Agent Monotherapy and Associations Including Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: Literature Review and Meta-Analysis of Randomized Trials

被引：8

作者：

Delpech, Celia ^{[1
]}

Laborne, Francois-Xavier ^{[2
]}

Hilliquin, Pascal ^{[1
]}

机构：

[1] Ctr Hosp Sud Francilien, Dept Rheumatol, F-91100 Corbeil Essonnes, France

[2] Ctr Hosp Sud Francilien, Clin Res Unit, F-91100 Corbeil Essonnes, France

来源：

JOURNAL OF CLINICAL MEDICINE | 2023年 / 12卷 / 01期

关键词：

rheumatoid arthritis; DMARDs (synthetic); biologic agents; systematic reviews; meta-analysis; NECROSIS-FACTOR-ALPHA; BLIND CLINICAL-TRIAL; TOCILIZUMAB MONOTHERAPY; METHOTREXATE THERAPY; COMBINATION THERAPY; INADEQUATE RESPONSE; PLUS METHOTREXATE; PHASE-III; MULTICENTER; ETANERCEPT;

D O I：

10.3390/jcm12010286

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: Update the available evidence comparing biologic disease-modifying antirheumatic drugs (bDMARDs) in combination with conventional synthetic disease-modifying antirheumatic drugs (CsDMARDs) to bDMARDs in monotherapy in patients with rheumatoid arthritis. Methods: Research was limited to randomized controlled trials. Major outcome: ACR 20 response criteria at 24 weeks. Secondary outcomes: clinical and radiographic criteria at week 24, 52 and 104. Results: 23 trials (6358 patients), including seven bDMARDs and one other molecule: Anbainuo (anti-TNF-R). No study satisfied our search criteria for anakinra, certolizumab and infliximab. Compared to bDMARD monotherapy, combination therapy gives a better ACR 20 at 24 weeks (RR: 0.88 (0.84-0.94)) in fixed and random effect models, and this result is sustained at 52 and 104 weeks. The results were mostly similar for all other outcomes without increasing the risk of adverse effects. Conclusion: This meta-analysis confirms the superiority of combination therapy over monotherapy in rheumatoid arthritis, in accordance to the usual guidelines.

引用

页数：16

共 67 条

[1] Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis [J].

Alfonso-Cristancho, Rafael ;

Armstrong, Nigel ;

Arjunji, Ramesh ;

Riemsma, Rob ;

Worthy, Gill ;

Ganguly, Rita ;

Kleijnen, Jos .

CLINICAL RHEUMATOLOGY, 2017, 36 (01) :25-34

[2] OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].

BEGG, CB ;

MAZUMDAR, M .

BIOMETRICS, 1994, 50 (04) :1088-1101

[3] Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial [J].

Bijlsma, Johannes W. J. ;

Welsing, Paco M. J. ;

Woodworth, Thasia G. ;

Middelink, Leonie M. ;

Petho-Schramm, Attila ;

Bernasconi, Corrado ;

Borm, Michelle E. A. ;

Wortel, Cornelis H. ;

ter Borg, Evert Jan ;

Jahangier, Z. Nazira ;

van der Laan, Willemijn H. ;

Bruyn, George A. W. ;

Baudoin, Paul ;

Wijngaarden, Siska ;

Vos, Petra A. J. M. ;

Bos, Reinhard ;

Starmans, Mirian J. F. ;

Griep, Eduard N. ;

Griep-Wentink, Joanna R. M. ;

Allaart, Cornelia F. ;

Heurkens, Anton H. M. ;

Teitsma, Xavier M. ;

Tekstra, Janneke ;

Marijnissen, Anne Carien A. ;

Lafeber, Floris P. J. ;

Jacobs, Johannes W. G. .

LANCET, 2016, 388 (10042) :343-355

[4] Adherence to Methotrexate in Rheumatoid Arthritis: A Danish Nationwide Cohort Study [J].

Bliddal, Henning ;

Eriksen, Stine A. ;

Christensen, Robin ;

Lorenzen, Tove ;

Hansen, Michael S. ;

Ostergaard, Mikkel ;

Dreyer, Lene ;

Luta, George ;

Vestergaard, Peter .

ARTHRITIS, 2015,

[5] The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[6]

Buckley Felicity, 2015, J Manag Care Spec Pharm, V21, P409

[7] Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial [J].

Burmester, Gerd R. ;

Lin, Yong ;

Patel, Rahul ;

van Adelsberg, Janet ;

Mangan, Erin K. ;

Graham, Neil M. H. ;

van Hoogstraten, Hubert ;

Bauer, Deborah ;

Ignacio Vargas, Juan ;

Lee, Eun Bong .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (05) :840-847

[8] Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial [J].

Burmester, Gerd R. ;

Rigby, William F. ;

van Vollenhoven, Ronald F. ;

Kay, Jonathan ;

Rubbert-Roth, Andrea ;

Kelman, Ariella ;

Dimonaco, Sophie ;

Mitchell, Nina .

ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (06) :1081-1091

[9] A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis [J].

Chen, Xiao-Xiang ;

Dai, Qing ;

Huang, An-Bin ;

Wu, Hua-Xiang ;

Zhao, Dong-Bao ;

Li, Xing-Fu ;

Hu, Shao-Xian ;

Yang, Nan-Ping ;

Tao, Yi ;

Xu, Jian-Hua ;

Jiang, Lin-Di ;

Bao, Chun-De .

CLINICAL RHEUMATOLOGY, 2013, 32 (01) :99-108

[10] Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study [J].

Combe, B. ;

Codreanu, C. ;

Fiocco, U. ;

Gaubitz, M. ;

Geusens, P. P. ;

Kvien, T. K. ;

Pavelka, K. ;

Sambrook, P. N. ;

Smolen, J. S. ;

Khandker, R. ;

Singh, A. ;

Wajdula, J. ;

Fatenejad, S. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (07) :1146-1152

← 1 2 3 4 5 6 7 →